# Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

> **NCT07185256** · PHASE1,PHASE2 · RECRUITING · sponsor: **Opus Genetics, Inc** · enrollment: 10 (estimated)

## Conditions studied

- ARB
- BVMD
- Autosomal-Dominant Bestrophinopathy
- Best Vitelliform Macular Dystrophy

## Interventions

- **GENETIC:** OPGx-BEST1

## Key facts

- **NCT ID:** NCT07185256
- **Lead sponsor:** Opus Genetics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2030-08
- **Final completion:** 2030-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185256, "Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07185256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*